Detalles de la búsqueda
1.
Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.
J Gen Intern Med
; 36(1): 92-99, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32875501
2.
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.
Lancet Oncol
; 19(11): 1504-1515, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30316827
3.
The importance of body composition in patients with prostate cancer receiving radiotherapy.
Cancer
; 129(5): 668-670, 2023 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36579471
4.
Reconciling outcomes for Black men with prostate cancer within and outside the Veterans Health Administration.
Cancer
; 127(3): 342-344, 2021 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33036061
5.
Quantitative comparison of automatic and manual IMRT optimization for prostate cancer: the benefits of DVH prediction.
J Appl Clin Med Phys
; 16(2): 5204, 2015 Mar 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-26103191
6.
Proton-beam therapy after radical prostatectomy: Continued DVH idolatry?
Cancer
; 125(23): 4136-4138, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31503326
7.
Palliative radiotherapy for prostate cancer.
Oncology (Williston Park)
; 28(4): 306-12, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24839802
8.
Does the multidisciplinary approach improve oncological outcomes in men undergoing surgical treatment for prostate cancer?
Int J Urol
; 21(12): 1215-9, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-25041422
9.
Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415.
Prostate Cancer Prostatic Dis
; 27(1): 95-102, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36849728
10.
Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.
Prostate Cancer Prostatic Dis
; 2024 Feb 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-38388778
11.
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
J Clin Oncol
; : JCO2302445, 2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38759121
12.
Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer.
Prostate Cancer Prostatic Dis
; 26(1): 30-40, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36203051
13.
Toxicity and Outcomes of Moderately Hypofractionated Radiation for Prostate Cancer With Seminal Vesicle Involvement.
Adv Radiat Oncol
; 8(5): 101252, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37408675
14.
Neighborhood Deprivation and Rurality Associated With Patient-Reported Outcomes and Survival in Men With Prostate Cancer in NRG Oncology RTOG 0415.
Int J Radiat Oncol Biol Phys
; 116(1): 39-49, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36736921
15.
Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center.
J Urol
; 187(1): 103-8, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-22088334
16.
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group.
BJU Int
; 109 Suppl 1: 22-9, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-22239226
17.
Quantitative analysis of the factors which affect the interpatient organ-at-risk dose sparing variation in IMRT plans.
Med Phys
; 39(11): 6868-78, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23127079
18.
Hypofractionation for prostate cancer: tested and proven.
Lancet Oncol
; 17(8): 1020-1022, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27339117
19.
Impact of Race on Outcomes of High-Risk Patients With Prostate Cancer Treated With Moderately Hypofractionated Radiotherapy in an Equal Access Setting.
Fed Pract
; 39(Suppl 3): S35-S41, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36426110
20.
Methodological Comparison of Mapping the Expanded Prostate Cancer Index Composite to EuroQoL-5D-3L Using Cross-Sectional and Longitudinal Data: Secondary Analysis of NRG/RTOG 0415.
JCO Clin Cancer Inform
; 6: e2100188, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35776901